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Wheat is a major source of nutrition, though in susceptible people it can
elicit inappropriate immune responses. Wheat allergy and non-celiac wheat
sensitivity are caused by various wheat proteins, including alpha-amylase
trypsin inhibitors (ATIs). These proteins, like the gluten proteins which can
cause celiac disease, are incompletely digested in the stomach such that
immunogenic epitopes reach the lower digestive system where they elicit
the undesirable immune response. The only completely effective treatment
for these immune reactions is to eliminate the food trigger from the diet,
though inadvertent or accidental consumption can still cause debilitating
symptoms in susceptible people. One approach used is to prevent the
causal proteins from provoking an immune reaction by enhancing their
digestion using digestive protease supplements that act in the stomach
or intestine, cleaving them to prevent or quench the harmful immune
response. In this study, a digestive supplement enriched in caricain, an enzyme
naturally present in papaya latex originally designed to act against gluten
proteins was assessed for its ability to digest wheat ATIs. The digestion
efficiency was quantitatively measured using liquid chromatography-mass
spectrometry, including examination of the cleavage sites and the peptide
products. The peptide products were measured across a digestion time
course under conditions that mimic gastric digestion in vivo, involving the
use of pepsin uniquely or in combination with the supplement to test
for additive effects. The detection of diverse cleavage sites in the caricain
supplement-treated samples suggests the presence of several proteolytic
enzymes that act synergistically. Caricain showed rapid action in vitro against
known immunogenic ATIs, indicating its utility for digestion of wheat ATIs in
the upper digestive tract.
KEYWORDS

alpha-amylase/trypsin inhibitor, proteomics, digestion, prolyl endopeptidase,
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Introduction

is to avoid the trigger by following a lifelong glutenfree diet. However, given the preponderance of cereals
in the modern diet there remains a risk that people
inadvertently consume wheat, barley or rye in processed
foodstuffs, medications, or in food contaminated during
preparation or the supply chain. Various attempts have
been made to detoxify gluten and the immune reactive
proteins present in cereal products (25), including the
use of digestive enzyme supplements that are taken orally
and claim to degrade gluten (26). These are an emerging
treatment option for inadvertent gluten consumption
that directly targets dietary proteins (27). There is an
increasing number of commercially available enzyme
supplements that typically contain different types of
bacterial, fungal or plant proteases. It is important
to consider the scientific evidence regarding their
efficacy before use.

Wheat is a high-quality source of vitamins, minerals,
and protein, though for a subset of the population wheat
proteins can elicit one of several enteric immune responses
that reduce and threaten health quality. Coeliac disease
(CD) affects approximately 1.4% of the population (1),
though half of the cases may be undiagnosed (2). In
CD, incompletely digested peptides derived from gluten
proteins contain specific epitopes (3–5) that initiate an
immune response, and a cascade of symptoms leads to
inflammation and enteropathy (6). The epitopes that initiate
CD are well documented (7, 4, 8) and are typically found
in gluten proteins namely gliadins and glutenins. While
gluten proteins are established antigens to those with
CD and contribute to wheat allergies, non-gluten wheat
proteins are potential allergens and antigens capable of
causing wheat allergy (WA), baker’s asthma (BA), nonceliac wheat sensitivity is (NCWS), as well as CD (9, 10,
4). Other wheat proteins with a known immune reactive
potential include the alpha-amylase/trypsin inhibitor (ATIs)
which themselves inhibit proteases and are resistant to
digestion. ATIs also contain specific epitopes that can
contribute to symptoms in WA, BA (4, 11, 12), and the
related disorder wheat-dependent exercise-induced anaphylaxis
(13). NCWS occurs when wheat consumption activates the
innate immune system and causes enteropathy without
serological evidence for both CD and WA (14). Proteins
known to be related to NCWS include various subclasses of
ATIs (15).
ATIs are members of the prolamin superfamily that
share common structural features due to their conserved
cysteine skeleton (15, 16) and can be grouped into
monomeric, dimeric and chloroform-methanol (CM)
soluble proteins (17). ATIs can be detected in most of
the cereals, and an immune response against homologous
proteins from barley or rye have been confirmed (11, 18).
The ATI CM proteins elicit an IgE response in people
with BA (19), and typically exhibit inhibitory activity
against specific amylases or proteases of plant pests (20,
21). Monomeric and dimeric ATIs are also known to be
related to BA while a subclass of ATIs, the dimeric ATI
0.19 proteins, contribute to symptoms associated with CD
(22). ATIs may have an inhibitory effect against trypsin
and/or amylase from bovines and insects, suggesting a
function in plant defense mechanisms. They are digestible
by other gastrointestinal proteases including pepsin or
chymotrypsin (23), though digestion may release peptides
that serve to increase rather than remove the inhibitory
activity (24).
There is currently no cure for CD and allergies
caused by cereals. The only proven treatment for CD
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Papaya latex is a source of enzymes used in the food
industry and medicine (28, 29). Crude extract has long been
known to digest wheat proteins ex vivo, and reduce wheat
immunogenicity in susceptible patients (30). It contains the
proteases papain, chymopapain, and glutamine cyclotransferase
(31, 32), as well as the cysteine protease caricain [EC 3.4.22.30,
also known as papaya proteinase omega (33)] which in
prior clinical studies has been shown to eliminate the
immune reactive proteins leading to a decreased level of
immune response (34, 35). It degrades wheat gliadin (36), and
recent in vitro research has demonstrated that a supplement
enriched in caricain was the most effective and rapid enzyme
supplement at digesting gliadins (26). This was assessed using
enzyme-linked immunosorbent assays that are commercially
available and will assess the gluten content but not other
immunogenic wheat proteins such as ATIs. While it was
primarily designed to detoxify inadvertently consumed dietary
gluten, caricain may also be able to reduce the effect of
other immune-reactive components in the wheat grain, such
as ATIs. To measure the efficacy of the caricain enriched
digestive supplement against ATIs, one must either develop
and characterize monoclonal antibodies or use an alternative
technique such as mass spectrometry (MS), which offers
several advantages including higher sensitivity, detecting
protein-specific sequence information, and measuring single
peptides in a label-free manner. To this end, databases of
proteins and epitopes of interest, and sample preparation
methods and instrumentation that yield reproducible
results exist and enable the comprehensive detection and
quantification of immunogenic peptides, before and after
in vitro digestion.
In this project, we developed proteomics methods to
investigate and monitor the digestive effect of a caricainenriched digestive supplement (GluteGuard) on wheat ATIs to
understand its efficacy in vitro.
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Materials and methods

Protein Pilot software v. 5.0.3 with the Paragon algorithm
(SCIEX) was used to identify proteins in experimental data.
Obtained spectral libraries were searched against a database
of Triticeae proteins collected from the Uniprot database
(version May 2019) appended with translated gene models
obtained from high resolution genome sequencing data of
Triticeae species (Ensembl plants), digested in silico with trypsin
or chymotrypsin as appropriate. ATI proteins were precisely
identified in experimental data using conserved protein domain
information and manually aligned and analyzed for sub-type
annotation using CLC Genomics Workbench v. 21 software
platform (Qiagen, Aarhus, Denmark).

Caricain action on amylase trypsin
inhibitors in vitro
Baseline characterization of amylase trypsin
inhibitors in wheat protein extract
To generate protein samples representing the full range
of wheat ATIs, samples were generated using an isopropanolbased extraction solvent containing dithiothreitol (DTT) that
is known to enrich ATIs (37). Briefly, grain samples from the
commercial bread wheat cultivar Baxter were ground into fine
powder using a mixer mill (model MM400 Retsch, Germany).
Four replicates of 20 mg flour were weighed for each variety, and
10 ml/g of extraction solvent 55% v/v iso-propanol (IPA)/2%
w/v DTT (IPA-DTT) was added. Samples were mixed by vortex,
incubated for 30 min at 50◦ C in a thermomixer (Thermo
Scientific), and centrifuged for 10 min.
An aliquot (100 µl) of the IPA-DTT extract was applied
to a 3 kDa MWCO filter (Merck, Bayswater, Australia),
and processed using a filter-aided sample preparation (FASP)
method. Briefly, proteins were alkylated using 25 mM
iodoacetamide (Sigma, St Louis MO, United States), washed
with 25 mM ammonium bicarbonate pH 8.4 (AmBic), before the
proteins remaining on the filter were digested using sequencinggrade modified trypsin or chymotrypsin (Promega, Alexandria,
Australia) added at a ratio of 50:1 protein-to-enzyme. Digested
peptides were collected by centrifugation, washed with AmBic,
centrifuged again, and lyophilized in a Speedvac (Thermo
Scientific). Dried samples were then reconstituted in 100 µl of
1% formic acid (FA) and subjected to LC-MS/MS.

Measuring rate of enzyme supplement action
Wheat protein extract (15 ml) was generated from Baxter
flour using IPA-DTT extraction solution by adding 1.5 mg flour
to 50 ml Falcon tubes and adding 15 mL of IPA-DTT solvent.
Samples were mixed by vortex, incubated for 60 min on a
plate shaker with agitation, and centrifuged for 10 min before
the supernatant was stored at -80◦ C in 7 ml aliquots for the
subsequent time-course experiments.
GluteGuard digestive supplements were provided by
Glutagen Pty Ltd. Caricain solution was prepared by dissolving
one GluteGuard tablet in 9 mL pH 3 acetic acid solution. This
was centrifuged and the supernatant diluted 1:9 in 50 mM
ammonium bicarbonate pH 7.0 (AmBic) which was diluted
a further 10× when added to the reaction vessel in time
course experiments. All enzyme solutions were made fresh for
each experiment.
Time-course experiments were then performed using
caricain after which the wheat protein digests were further
cleaved by trypsin, or chymotrypsin (used as experimental tools)
to monitor fully tryptic and chymotryptic peptides. Each time
course experiment had four replicates containing 1 mL of wheat
protein extract and 800 µl of 50 mM AmBic pH 7 as diluent
had 200 µl of caricain solution added to it, then 200 µl samples
were taken at time points precisely 5, 15, 30, 45, and 60 min
after adding caricain. These samples were added to 3 kDa
filters containing 200 µl of Stop Solution (pH 3 acetic acid)
to shift the pH away from the operational range of caricain
(pH 4.5–7.0) and were immediately centrifuged at 20,800 g for
15 min. A zero-minute control was made by taking 180 µl
wheat protein extract prior to adding caricain and adding to a
3 kDa filter containing 220 µl of Stop Solution. The time-course
experiment was performed once for trypsin digestion, and once
for chymotrypsin digestion.
The primary filtrate from each time point (Filtrate 1)
was collected for digestion specificity analysis. The protein
remaining on top of the filter was washed with 100 µl 8 M
urea in 0.1M Tris HCl pH 8.4. Reduced cysteine residues were
alkylated by adding 100 µl of 25 mM iodoacetamide in 8M
urea 0.1 M Tris HCl pH 8.4 and leaving for 20 min in the
dark at room temperature. The filter was then centrifuged and

Discovery proteomics
Discovery data was generated using an Eksigent nanoLC415
(Eksigent, Dublin, CA, United States) liquid chromatography
system coupled with a TripleTOF 6600 (SCIEX, Redwood
City, CA, United States) mass spectrometer operating in data
dependent analysis (DDA) mode. In brief, 1 µl of sample
was desalted for 5 min on a ChromXP C18 (3 µm, 120Å,
10 × 0.3 mm) trap column at a flow rate of 10 µL/min
solvent A and separated on a ChromXP C18 (3 µm, 120Å,
150 mm × 0.3 mm) column at a flow rate of 5 µL/min. The
solvents used were (A) 5% DMSO, 0.1% FA, 94.9% water and
(B) 5% DMSO, 0.1% FA, 90% acetonitrile, 4.9% water. A linear
gradient from 5 to 45% B over 40 min was employed, followed
by 45–90% B for 5 min, a 5 min hold at 90% B, return to 5% B
over 1 min, and 14 min of re-equilibration. The eluent from the
HPLC was directly coupled to the DuoSpray ion source of the
TripleTOF 6600 MS. The ion spray voltage was set to 5500 V; the
curtain gas was set to 138 kPa (20 psi), and the ion source gas 1
and 2 (GS1 and GS2) were set to 20 and 15 psi, respectively. The
heated interface was set to 150◦ C.
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search algorithm of CLC Genomics Workbench v. 21 (Qiagen,
Aarhus, Denmark).

washed with AmBic twice to perform buffer replacement. Filters
were moved to clean collection tubes, and 200 µl of 20 µg/mL
trypsin or alternatively chymotrypsin (Promega, Alexandria,
Australia) in AmBic with 1mM CaCl2 were added to each filter
and the samples incubated overnight at 37◦ C. Digested samples
were centrifuged for 15 minutes at 20,800 g and washed with
200 µl of 50 µl AmBic pH 8.4. The filtrates of digested samples
were combined and lyophilized, and peptides reconstituted in
100 µl of 1% FA for later analysis per targeted proteomics as
described below.

Testing the effect of gastric pepsin on
the digestive supplement efficiency in
non-reducing conditions
Notably, using DTT and alkylation to reduce and stabilize
wheat protein cysteine residues will denature wheat proteins and
improve protein solubilization during sample preparation, and
thereby boost proteome coverage during discovery MS, but it
will render proteins more accessible for digestion by a digestive
enzyme supplement. To better assess the digestive supplement
action under the non-reducing conditions, present in the human
digestive system, we adapted the extraction solvent to use 70%
ethanol instead of IPA, excluded DTT, and added steps to test the
effect of the gastric enzyme pepsin. In this way, proteins were not
denatured by reducing conditions and may be more resistant to
digestion than in the IPA-DTT extraction. Digestion efficiency
of the Gluteguard supplement was compared to a commercially
available Aspergillus niger-derived prolyl endopeptidase (AnPep) supplement, containing 360 mg of active ingredient (DSM
Nutritional Products SA, Kaiseraugst, Switzerland) per capsule.
Experiments using An-Pep were prepared similar to caricain:
one capsule was initially dissolved in 9 mL pH 3 acetic acid,
before diluting 1:9 in AmBic buffered to pH 3 (the optimum pH
of An-Pep) with acetic acid and was further diluted 10x when
added to the reaction vessel in time course experiments.

Digestion specificity
Caricain digestion specificity was determined by a detailed
sequence analysis using discovery proteomics data taken on the
primary filtrate digests. To get this, primary filtrate samples were
lyophilized, and reconstituted in 100 µl of 1% FA, then subjected
to LC-MS/MS analysis using the same discovery proteomics
methods as described above. First, the 60 min time point results
from trypsin and chymotrypsin digested extracts were searched
using ProteinPilot v. 5.0.3 using the same database as described
above with the enzyme setting set to ’no enzyme’. Peptides
identified with > 95% confidence in Protein Pilot were used.
The first three (P’1, P’2 and P’3) and last three (P3, P2, P1)
amino acid residues were determined for each peptide and the
frequency of P’1 – P1 and P’2P’1 – P1P2 pairs calculated.

Targeted proteomics
ATI proteins were identified from discovery data using
conserved protein domain information obtained from Pfam
and InterPro databases and manually aligned for sub-type
annotation. Fully tryptic and chymotryptic intense peptides
were used to develop multiple reaction monitoring (MRM)
methods. Peptides were mapped to the identified sequences
using CLC Genomics Workbench v21 and grouped to
define ATI sub-type specific peptide sets. MRM transitions
were determined for each peptide using the precursor ion
and fragment ion m/z values obtained from the discovery
proteomics analysis. Pooled samples of the trypsin or
chymotrypsin digests were separated on a Exion LC system
(SCIEX) and analyzed on a 6500 + QTRAP MS instrument
(SCIEX). At least three peptides and four transitions were
considered for each protein. From these, three intense
transitions with matching peak shape and retention time
values were selected for scheduled MRM analysis. Peaks were
integrated using Skyline software package (38). The peak areas
of the transitions obtained from the same peptide were summed
and replicate values were subjected to statistical analysis using
GraphPad Prism 8. The resulting peak area measurements
were normalized to the 0 min time points, annotated with ATI
subtype-specific information, and visualized in the Morpheus
R package. Known linear epitopes associated with BA (19) and
CD (39) were used for epitope mapping analysis using the Motif
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Extraction under non-reducing conditions
The commercial bread wheat cultivar Baxter was used in
these analyzes. Approximately 3 g flour was weighed into eight
50 ml Falcon tubes and proteins extracted by adding 10 ml/g
70% ethanol in non-reducing conditions. Flour samples were
vortexed thoroughly, before being sonicated for 15 min and
vortexed again. They were then mixed for 30 min on a plate
shaker operating at 600 rpm and centrifuged at 4,500 rpm
for 10 min to form a pellet. The tubes were then decanted
into a single flask, and aliquoted and stored at -80◦ C until
needed. The protein concentration in this extract was measured
at 2.07 mg/ml using a Bradford assay (Sigma) prior to freezing.
Working caricain and An-Pep solutions were made fresh on the
day of use as described above.
For caricain experiments, a digestion time course
experiment was designed with an initial pepsin step to simulate
the gastric phase of digestion. The gastric pre-treatment step
consisted of four replicate reaction vessels containing 280 µl
of water, 100 µl of 1% HCl, 1 ml of protein extract solution,
and either 20 µl of 200 µg/ml pepsin in acetic acid pH 3 or
20 µl of acetic acid pH 3 as a control. These were combined
and digested for 60 min at 37◦ C, after which 140 µl was taken
as the 0 min time point sample and added to 3 kDa filters
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FIGURE 1

(A) Two ATI CM3 protein isoforms (P17314 and A0A3B6JR20) detected in the flour samples with TLR4 epitopes and monitored MRM peptide
sequences flagged. (B) Polypeptide sequence of representative dimeric (C3VW96) and monomeric (C4P5I8) ATI proteins, with BA epitopes and
peptide sequences targeted for quantification.

FIGURE 2

Overall trends of ATI peptide digestibility in Baxter. Peptide peak area values of all peptides included in the analysis are presented in the
individual replicates and monitored during the digestion analysis. Majority of the peptides were more than 95% reduced within 5 min of
digestion, including those present in one or more subtypes of ATIs that are immune-reactive.
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that were pre-loaded with 260 µl AmBic pH 8.4 to quench
pepsin activity. To the reaction vessel 600 µl of AmBic pH 8.4
was added to neutralize acid and bring pH to 7, quenching
pepsin activity. The reaction vessel was then vortexed, 200 µl
of working caricain solution was added, vortexed again, and
samples (200 µl) were collected from the reaction vessel at
time points precisely 1, 5, 15, 30, 45, and 60 min after adding
caricain solution. The 1-minute sampling time point was
added to capture rapid digestion suggested by the experiments
above. Samples taken at each time point were applied to 3 kDa
filters that were pre-loaded with 200 µl pH 3 acetic acid to
quench enzyme activity and were centrifuged immediately at
20,800 g for 15 min. Samples were subjected to a FASP in a
protocol that excluded reduction and alkylation steps such
that the subsequent enzymatic digestion (using trypsin, and
in independent experiments chymotrypsin) better reflected
digestion in the digestive tract in vivo. Control experiments
were also included where caricain was excluded and substituted
for blank solution (50 mM AmBic pH 7). In this way and in vitro
modeling of ATI digestion was tested, and experiments with
and without pepsin, with and without caricain, and with trypsin
or chymotrypsin used in FASP for analytical purposes inform
our understanding of caricain action in vivo. Combinations of
enzymes in these experiments are shown in Supplementary
Table 1.
The time course experiment was adapted to be used with
An-Pep, which is active in the low pH environment of the
stomach. The time course sampling was performed throughout
the 60 min gastric digestion step, and there was no intestinal
digestion. Four replicate reaction vessels each contained 1 ml
protein extract solution, 780 µl of 1% HCl as diluent, and either
20 µl of 200 µg/ml pepsin in 1% HCl or 20 µl of blank 1% HCl.
Vessels were vortexed and a 178 µl time point sample was taken
immediately and added to 3 kDa filters containing AmBic pH
8.4 to quench enzyme activity, and centrifuged. To the reaction
vessel either 200 µl An-Pep or 200 µl acetic acid were added and
samples collected after 1, 5, 15, 30, 45, and 60 min, and added to
filters containing AmBic pH 8.4, centrifuged, and processed by
FASP again excluding reduction and alkylation steps. There were
experiments run with and without pepsin, with and without
An-Pep, and with trypsin or chymotrypsin used in FASP as
summarized in Supplementary Table 1.

subtypes, including six CM ATIs (CM1, CM2, CM3, CM16,
CM17, CM Hageman), monomeric ATIs, and two sub-types of
dimeric ATIs (dimeric-0.19 and -0.53 ATIs) (Supplementary
Table 2). Epitope mapping analyzes confirmed the presence of
the TLR4 epitopes (39) in sequences from the CM3 ATI subtype and BA-related B-cell epitopes (19, 39) in the dimeric and
monomeric ATI sequences (Supplementary Table 2). Using
peptide mapping with 100% sequence identity we categorized
the quantified peptides into sets that are specific for the
following major ATI types: dimeric, dimeric-0.19, monomeric,
CM3, CM16-CM17 and CM1 ATIs. Peptides overlapping with
published CD (39) or BA associated epitopes (19) were included
in the analysis. A total of 69 fully tryptic peptides identified from
the ATI proteins were monitored using LC-MRM-MS. Figure 1
shows two identified CM3 sequences with peptides known to
be related to the TLR4 response (39). These TLR4 epitopes
were partially overlapping with fully tryptic MRM peptides.
Epitopes associated with BA were detected in the monomeric
and dimeric ATIs.

Enzymatic digestion time course
Targeted proteomics was used to quantify fully tryptic
and chymotryptic ATI peptides in undigested wheat extracts
(0 min time point), and the relative abundance after digestion
by caricain for 5, 15, 30, 45, and 60 min was measured.
Practically, this was achieved by using trypsin or chymotrypsin
as a biochemical tool to liberate detectable peptides during FASP
that would be suitable for MS measurement. Peptide peak areas
were recorded for each MRM transition in Baxter samples, each
peptide was normalized to its’ baseline peak area at 0 min, and
abundance values visualized as a heatmap (Figure 2).
Comparison of the ATI subtypes show all subtypes have
been successfully digested by caricain within 5 min (Figure 2).
This includes multiple ATI subtypes known to exhibit immune
reactivity, as presented in turn in the following sections.

Abundance changes in the amylase
trypsin inhibitor subtypes with known
immune reactivity

Results

Altogether eight dimeric ATI isoforms were detected, one of
which represents the CD-associated dimeric-0.19 ATI subtype.
Most of the dimeric ATI isoforms contained two epitopes
associated with BA (19), and the monomeric ATI isoforms
contained 14-15 BA epitopes (Supplementary Table 2). We
were able to detect several caricain-specific cleavage sites both
within and around the epitopes (Supplementary Figure 1) and
were able to monitor the abundance of peptides that span their
sequence by LC-MRM-MS (Figure 1). In all cases, these peptides

Characterizing extractable wheat
amylase trypsin inhibitors
In the initial discovery proteomics experiment, 265 proteins
were identified from IPA/DTT extracts of cultivar Baxter. Of
these proteins, 22 ATI isoforms were identified. The precise
characterization of the ATI sequences resulted in nine ATI
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FIGURE 3

Abundance changes of ATI type-specific peptides. In all detectable ATI subtypes, peptide abundance (reported as MRM peak area, log scale)
decreased by orders of magnitude within 5 min and any change in abundance that occurred after this time was minimal. Median values of ATI
subtype-specific peptide groups are labeled with colored dots. Dot size represents the number of peptides, sub-type specific data distribution
and heterogeneity is highlighted using violin plots.

FIGURE 4

Cleavage sites observed in caricain-digested peptides. Dot color and size indicates frequency of observed P1-P1’ pairs in primary filtrate
peptides. The observed caricain cleavage sites demonstrate preferential cleavage between aliphatic residues at R-S, followed by A-A, S-S, L-T,
and A-C.
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importance of aliphatic residues both in P1’ and P2’
positions (Figure 4).

were present prior to caricain action, but dramatically decreased
in abundance within 5 min (Figure 2).
Dimeric-0.19 ATIs were represented by the protein isoforms
Q5UHH6 and Q5UHH8. Compared to dimeric ATIs one
peptide, ECCQQLADISEWCR, was identified that was specific
for this sub-type and two peptides, SGPWMCYPGYAFK and
LTAASITAVCK, were shared between dimeric-0.19 and -0.53
ATIs. Interestingly, the ECCQQLADISEWCR peptide could
only be measured at 0 min and presumably completely digested
in later time points.
Monomeric ATIs are enriched in peptides that can trigger
immune response in BA. There were four distinct isoforms of
monomeric ATIs identified. All monitored peptide sequences
showed a significant decrease in peptide abundance in the early
stages of protein digestion (Figures 2, 3).
There were two CM3 ATI protein isoforms detected, that
differ in their protein sequences (P17314 and A0A3B6JR20).
Both proteins include the TLR4 epitopes reported by Cuccioloni
et al. (39) and fully tryptic peptides overlapping with these
epitopes following caricain digestion have been identified
in our analysis (Figure 1 and Supplementary Figure 1).
All the CM3 peptides show a significant decrease in their
abundance after 5 min of digestion. Monitoring peptides
overlapping with the epitopes demonstrate that caricain
efficiently cleaves these epitopes within 5 min (Figures 2,
3).

Impact of gastric pretreatment on
digestion efficiency
The 69 fully tryptic and chymotryptic ATI peptides
monitored previously were then searched for in samples
extracted and digested under non-reducing conditions. The
additional effect of the gastric enzyme pepsin on ATI digestion
was also quantified, to better reflect the human digestive system.
Of the 69 peptides in the previous MRM transition list,
47 were detected in samples extracted with 70% ethanol as
extraction solvent at sufficient levels for quantitation. These
peptides primarily represent the CM sub-class of ATIs (CM1,
CM3, CM16, and CM17), while monomeric and dimeric ATIspecific peptides were under-represented. Most of the peptides
showing good intensities were those lacking cysteine residues in
their sequence, and those with cysteine were generally below the
threshold intensity. As the protein digestion workflow did not
incorporate reduction or alkylation, Cys-containing peptides
may contain disulfide linkages which would preclude their
detection or identification.
To account for differences in initial abundance, experiments
with caricain alone (Ccn) and caricain pre-treated with pepsin
(Ccn + Pep) had peptide abundance values normalized to
their 0 min time point value. The heatmaps below show
these 0-normalized abundance results, where blue shades
indicate a decrease, red an increase, and white a constant
value (Figure 5A). Similar assessments were made of AnPep alone (An-Pep) and with pepsin pre-treatment (AnPep + Pep) (Figure 5B).
The majority of monitored peptides were digested by
caricain under non-reducing conditions (Figure 5A). Despite
collecting samples at a time point 1 min after adding caricain,
the change between 0 and 1 min was generally greater than the
change between 1 and 60 min. Peptides from CM3, CM16/17,
dimeric ATIs, and to lesser of an extent monomeric ATIs
and CM Hageman ATIs decreased in abundance within 1 min
of digestion with caricain. Of note, peptide TSDPNSGVLK
specific to the ATI CM1 type showed an increase in abundance
in the caricain time course experiment, though this was not
seen when pepsin was used to simulate gastric digestion. This
shows that caricain alone leads to incomplete digestion of
CM1 proteins, though when acting in conjunction with pepsin
digestion is complete.
The mean relative change in peptide abundance over
60 min was calculated for each ATI-specific peptide group
for caricain, and caricain pre-treated with pepsin (Figure 6A).
The highest decrease in abundance (> 80%) was measured
in the dimeric ATI and ATI CM3 peptides, which indicates
that the main immunogenic ATIs can be degraded by this

Digestion specificity
Peptide sequences detected in the F1 filtrates were used
to determine the cleavage specificity of enzymes present
in the GluteGuard digestive supplement. Combinations
of amino acid residues present in P3, P2, P1 and P1’,
P2’, P3’ positions of the detected peptides detected from
ATI protein sequences were analyzed. Detected primary
filtrate peptide sequences were mapped to sequences using
100% sequence identity cut off, and extended peptides,
with 3 amino acid flanking regions in both directions
were extracted from the complete sequence data, and
further analyzed.
The most frequent combination was when the sequences
were cleaved before (N-terminal) an aliphatic amino acid
in all P1’, P2’ and P3’ positions combined with cleavage
after (C-terminal) an aliphatic in P3, hydroxylic in P2
and sulfur-containing in P1. When only the P1, P2
and P1’, P2’ positions are considered the most frequent
combinations mainly contain aliphatic residues in the
P1’ and P2’ positions, where P1’ is mostly A or V. This
is combined with aliphatic residues present in the P1
position, with glycine being the most frequent residue.
The ATI-specific caricain cleavage patterns confirm the
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FIGURE 5

Relative abundance changes of the tryptic ATI peptides digested by: caricain (A); and An-Pep (B); in non-reducing conditions in absence (left)
and presence (right) of pepsin. Each value (peptide peak area) was normalized to its own 0 time point value.

FIGURE 6

Peptide abundance after 60 min digestion expressed as a percentage of abundance in the 0 min time point. ATI CM16 and CM17 peptides
showed similar results and are grouped together (A) caricain significantly digests all ATI types except for CM Hageman and CM1, though in
conjunction with pepsin, caricain digests these too. (B) An-Pep does not digest ATI peptides within 60 min even in conjunction with pepsin.
Error bars indicate 95% confidence intervals.
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regions related to the TLR4 response or BA and facilitates
further digestion by intestinal proteases including trypsin
and chymotrypsin.

digestive supplement. All ATI types are digested by caricain
to different degrees. The CM16, CM17 and monomeric group
specific peptides were only reduced by 20–30%, and the overall
average abundance of ATI peptides after 60 min of digestion was
59.7% that of their abundance in the 0 min control. The presence
of pepsin did not significantly affect peptide digestibility except
in the case of CM1 peptides, where it significantly reduced
abundance. Digestion by An-Pep in the presence and absence
of pepsin confirmed that An-Pep is not able to digest ATIs
effectively (Figure 6B).

Comparing the protein extracts derived under experimental
(IPA/DTT) and simulated gastric (i.e., extracted in 70% ethanol
under non-reducing conditions) revealed that some proteins
were solubilized/extracted in IPA/DTT but not in the ethanol
solutions used. Those that were extracted and hence detectable
showed different responses to caricain according to the ATI
subtype they belong to, which in turn suggests that some
ATI types exhibit a resistance to digestion, perhaps due to
hinderance in structures stabilized by disulfide bridges. It
is likely that protein regions buried due to the compact
disulfide bridge stabilized structure of ATIs makes them
less prone to digestion, and contributes to their ability to
allergic reactions (39). Notably, the inclusion of a gastric
phase, practically implemented through use of pepsin, did not
enhance digestion.
An-Pep is another commercially available digestive
supplement for gluten-sensitive consumers, designed to act
upon gliadins. This test of its action against wheat ATIs revealed
limited An-Pep efficacy against some but not all ATI proteins
under non-reducing conditions, showing an overall lower
efficacy when compared to caricain. While ATI CM17 proteins
decreased in abundance after An-Pep digestion, CM1 peptides
were more abundant when pepsin is also present (Figure 6).
This digestion ability of An-Pep was not improved by the
presence of pepsin.
The varied digestion specificity analysis of caricainenriched digestive supplement (Figure 4) indicates that there
is more than one enzyme contained in the papaya latex
extract. While gluten protein digestion by this supplement
has been attributed to the enzyme caricain (26), this is
the first assessment of ATI digestion by this supplement.
Most cleavages observed in primary filtrate peptides occurred
where aliphatic residues are in both the P1’ and P1
positions, though this is more variability than would be
expected from a single enzyme. The most common cleavage
sites were R-S, followed by A-A, S-S, L-T, and A-C,
though more were also observed (Figure 4). The number
of glycine residues may account for some of the G-A and
G-V cleavages. The papaya protease papain (EC 3.4.22.2)
cleaves after R or K residues and before hydrophobic
residues, and would explain the R-S, as well as K-A and
R-L activity observed. The enzyme caricain (EC 3.4.22.30)
is reported to have broad specificity for peptide bonds
like papain (EC 3.4.22.2) and chymopapain (EC 3.4.22.6).
Future directions in this line of research might focus on
identifying the enzymes that cleave specifically at A-C: while
a tablet with multiple protease cleavage sites is evidently
effective at denaturing and digesting most ATIs, a more
concentrated protease may prove more potent against those that
resist digestion.

Discussion
In this study, we investigated the efficiency of a digestive
supplement enriched in caricain at digesting ATIs, a protein
group with known immune reactive potential in CD, food
allergy and NCWS. Under both reducing and non-reducing
conditions, caricain rapidly digested ATIs including the most
immunologically relevant ATI subtypes. With one exception,
multiple ATI proteins belonging to the dimeric, monomeric,
CM1, and CM3 subfamilies significantly decreased within 1 min,
leaving little signal at the 5 min and later time points. This rapid
action is similar to recent observations of caricain action on
wheat gliadin proteins (26). While it is possible that caricain
is not completely inactivated by the addition of pH 3 stop
solution, the large relative change between 0–5 min and the lack
of change between 5–60 min would reinforce the conclusion that
the enzyme acts rapidly in vitro, in conditions that resemble
human digestion. The sole exception was the CM1 peptide
TSDPNSGVLK in non-reducing conditions, which uniquely
increased in abundance with caricain. This is suggestive
of structural changes in the parent protein(s) instigated by
caricain, which liberates previously hidden protein regions
such that they are amenable to digestion by other digestive
enzymes. Importantly, when pepsin was used to simulate
gastric digestion the increase in TSDPNSGVLK abundance
was not noted, suggesting that the combination of pepsin
and caricain improved the digestibility of this protein in our
in vitro model.
The ATI identification rate is improved when proteins
are reduced during extraction. This is not surprising given
that ATIs exhibit trypsin inhibition, and their secondary
structure is stabilized by disulfide bridges, and it is consistent
that reduction and alkylation will both aid their extraction
and cause denaturation, removing their trypsin inhibitory
activity (16) and improving digestion by trypsin and
chymotrypsin. In non-reducing conditions, however, the
stable conserved structure of ATIs contributes to their poor
digestibility and means they can reach the intestine intact
where they are able to bind to the TLR4 receptor and instigate
an immune response. Our results suggest that caricain
effectively cleaves most ATI peptides including immune reactive
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